Gene Techno Science Co.,Ltd. acquired remaining 94.7% stake in Japan Regenerative Medicine Co., Ltd. from Noritsu Koki Co., Ltd. for ¥0.
February 16, 2020
Share
Gene Techno Science Co.,Ltd. (TSE:4584) acquired remaining 94.7% stake in Japan Regenerative Medicine Co., Ltd. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥0 on February 17, 2020. Gene Techno Science will acquire 121 million shares of Japan Regenerative. Japan Regenerative will operate as a subsidiary of Gene Techno Science. Japan Regenerative reported net assets of ¥230 million, total assets of ¥254 million, operating loss of ¥282 million and net loss of ¥285 million for the year ended March 31, 2019. The Boards of both, Gene Techno and Noritsu Koki resolved on the transaction.
Gene Techno Science Co.,Ltd. (TSE:4584) completed the acquisition of remaining 94.7% stake in Japan Regenerative Medicine Co., Ltd. from Noritsu Koki Co., Ltd. (TSE:7744) on February 17, 2020.
Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
KIDSWELL BIO CORPORATION 
